Imagine that a new medicine has survived ten years of experiments, arguments, grant committees, clinical trials, and regulator questions. It arrives, at last, in the hands of a physician as a forty-slide deck, two dense papers, a mechanism-of-action animation, and a crowded congress booth. The science has crossed the hardest distance in research. It now faces the strangest distance in business: the final metre between evidence and understanding.
Healthcare Consultancy Group made that metre its territory. HCG did not discover molecules or run hospitals. It worked on the translation layer around medicine - the scientific narrative, the publication plan, the advisory board, the regulatory rehearsal, the medical-education program, the digital experience, and the chart that a busy clinician might actually remember on Friday afternoon.
This sounds like marketing until you notice the unusual cast. HCG's own 2023 credentials counted more than 350 PhDs, MDs, and PharmDs among a team of more than 1,000. It also counted more than 150 digital strategists and creatives and over 30 regulatory specialists. The agency was built on a useful contradiction: scientific communication must be exact enough for the expert and clear enough for the exhausted.
HCG's real product was not content. It was comprehension under constraint.
The distance between “it works” and “it gets used”
HCG's customers were pharmaceutical, biotechnology, and medical-device companies. The users downstream were medical-affairs teams, healthcare professionals, payers, patients, and caregivers. That is a long relay race, and every handoff offers a fresh chance to lose the plot. A publication can be precise but unread. A beautiful campaign can overstep the evidence. A compliant document can arrive in the wrong channel, for the wrong audience, six months late.
The agency's answer was breadth with a scientific spine. Its teams handled market and product analysis, positioning, disease education, publication planning, key-opinion-leader engagement, congress support, medical writing, social strategy, websites, immersive experiences, and preparation for FDA advisory committees and European regulatory meetings. Omnicom ownership added reach, data, and technology. HCG's promise was that these disciplines would behave like one system rather than a bag of vendors.
Seven doors become one
For years, HCG was a family of specialist agencies: Chameleon, Health Science Communications, ProEd Communications, ProEd Regulatory, Synergy, The Scienomics Group, and an engagement group. The arrangement offered clients deep craft identities, but it also reproduced the thing clients were paying HCG to remove - seams.
In 2024, leadership reorganized the seven smaller agencies into one HCG. This was the first crack in the old model: the brand architecture had become less useful than the workflow. Medical affairs was expanding into real-world evidence, health economics, market access, health equity, social channels, and measurable behavior. A client did not need seven front doors. It needed the right experts to appear around one problem.
What changed their mind was not a single failed campaign. It was the accumulation of new audiences, new channels, fast-moving therapies, and a medical-affairs function expected to prove impact rather than merely produce outputs. HCG began talking less about the number of things made and more about whether a communication changed understanding, acceptance, or practice. That shift is harder than a rebrand because it changes what the work is for.
What the invoice buys
HCG was a business-to-business consultancy and agency. Clients bought retained relationships and projects, with engagements priced privately. The 2024 mix shows what mattered commercially: 51 percent of business came from commercial and marketing work, 29 percent from medical affairs, 11 percent from publications, and 9 percent from regulatory services. The supplied company data estimates annual revenue at $200 million, though HCG did not publish standalone audited accounts.
The visible cost was agency fees. The larger cost was coordination: scientific review, legal review, regulatory boundaries, specialist staffing, global adaptation, and version control. HCG's economic argument was that one integrated team could make those handoffs less expensive than a loose chain of vendors.
Scale gave the proposition weight. In 2024 HCG reported 65 active business clients and eight account wins. Earlier credentials claimed more than 35 ongoing strategic publication plans, more than 650 publications a year, and support for over 300 product launches. Those figures describe an agency that treated scientific storytelling not as occasional copywriting, but as an operating discipline.
A chart about hair, and a point about trust
The neatest example of the model is also the most visually modest. In 2025, HCG and creative-technology studio Cassette won a Communiqué Award for a Hair Regrowth Visualizer made for Pfizer. The tool converted complex alopecia-areata data into something people could see and discuss. It joined scientific, editorial, creative, video, digital, and client-service disciplines. The cleverness was not decoration. It was giving evidence a usable form.
That distinction matters in a field crowded with glossy claims. Good information design does not make the science louder; it makes the hierarchy clearer. HCG designer Paulo Estriga compared healthcare information to road signs: people navigating a complicated environment need the important signal before the scenery. Pictures alone can intrigue, words alone can specify, but the two together improve recognition and recall.
There was a cultural version of the same idea. HCG's “AMP THE TRUTH” campaign celebrated accurate evidence amid medical misinformation and raised £10,000 for World Child Cancer. It is a small number beside a global agency's revenue, but a revealing one: in medical communications, accuracy is both craft and reputation.
The trick worth stealing
The part another consultancy can copy is not the headcount. Start with one audience decision: what should this person understand, believe, or do differently? Put the subject expert, writer, designer, channel planner, and reviewer in the room before production begins. Create one evidence spine, then adapt it for each format. Measure the audience outcome, not the pile of deliverables. And keep the scientific reviewer close enough to improve the idea, not merely veto it at the end.
HCG also offers a warning about “integration.” It works when the underlying jobs share evidence and timing. A regulatory briefing, a congress presentation, and an HCP education tool can benefit from one narrative and one knowledge base. Merely placing unrelated teams beneath the same logo creates a larger directory, not a better answer.
The evidence is mature, teams share incentives, review happens early, and the client can define the audience change that matters.
Speed outruns substantiation, global consistency erases local context, or every discipline protects its own deliverable instead of the common outcome.
The agency disappears into the network
HCG's final lesson arrived through its own corporate evolution. Omnicom completed its combination with Interpublic in late 2025, then assembled a broader Omnicom Health Medical Communications operation. By 2026, Nina Hinchcliffe, HCG's former global chief executive, was leading medical affairs and publications in that larger unit. The old HCG capabilities had not vanished; they had become components in a wider machine.
There is an irony here. HCG spent years arguing that complex science needed fewer handoffs and a more connected system. Eventually, the agency itself was treated the same way. Whether a larger structure preserves the intimacy of specialist teams is the open question. But the logic is consistent: the audience does not care which box on the organization chart made the sentence. It cares whether the sentence helps.
That is the overlooked work behind modern medicine. Discovery produces possibility. Communication decides how much of that possibility can travel.